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A regional cancer network has been set up in the Rho ˆne-Alpes region in France. The aim of the project is to improve the
quality of care and to rationalize prescriptions in the network. In this network, we assessed the impact of the implementation
of a clinical practice guidelines project by assessing the conformity of practice with the guidelines and comparing this with the
conformity in an external matched control group from another French region without a regional cancer network. Four
hospitals (private and public) accepted to assess the impact of the clinical practice guidelines on the management of breast
and colon cancer in the experimental group and three hospitals (private and public) in the control group. In 1994 and 1996,
women with non-metastatic breast cancer (282 and 346 patients in the experimental group, 194 and 172 patients in the
control group, respectively) and all new patients with colon cancer (95 and 94 patients in the experimental group, and 89 and
118 patients in the control group, respectively) were selected. A controlled ‘before-after’ study, using institutional medical
records of patients with breast and colon cancer. The medical decisions concerning the patients were analyzed to assess their
compliance with the clinical practice guidelines. When medical decisions were judged to be non-compliant, we veriﬁed if they
were based on scientiﬁc evidence in a published article, if they were not, the medical decision was classiﬁed as having ‘no
convincing supporting scientiﬁc evidence’ The compliance rates were signiﬁcantly higher in 1996 than in 1994 in the
experimental group; 36% (126 out of 346) vs 12% (34 out of 282) and 46% (56 out of 123) vs 14% (14 out of 103)
(P50.001) for breast and colon cancer, respectively. Whereas, in the control group the compliance rates were the same for
the two periods; 7% (12 out of 173) vs 6% (12 out of 194) (P=0.46) and 39% (49 out of 126) vs 32% (31 out of 96), P=0.19.
In the experimental group, in 1994, 101 of the 282 medical decisions (36%) and 27 of the 103 (26%) for breast and colon
cancer, respectively, were classiﬁed as having ‘no convincing scientiﬁc evidence’ compare with 72 out of 346 in 1996 (21%) for
breast cancer, and 21 of the 123 (17%) for colon cancer P50.05. Whereas in the control group these results were 106 out
of 194 in 1994 (55%) and 90 out of 172 in 1996 (52%), P=0.65 for breast cancer and 28 out of 96 in 1994 (29%) and 30 out
of 126 in 1996 (24%), P=0.36 for colon cancer. The development and implementation strategy of the clinical practice
guidelines programme for cancer management results in signiﬁcant changes in medical practice in our cancer network. These
results would suggest that introducing guidelines with speciﬁc implementation strategy might also increase the compliance rate
with the guideline and ‘evidence-based medicine’.
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It has been shown that the simple distribution of guidelines and
published reports from consensus conferences does not change
physicians’ practice (Davis et al, 1992; Ferguson, 1995). Input to
the development of guidelines from local physicians, dissemination
of new information by local opinion leaders, guidelines or algo-
rithms linked with patients’ records, patients’ reminders,
outreach visits and chart review with feedback have all been incon-
sistently successful in enhancing physicians compliance with
guidelines (McDonald et al, 1984). The successful introduction of
clinical guidelines leading to signiﬁcant improvements in clinical
care depends on many factors including the clinical setting (Grilli
and Lomas, 1994), and the methods of development, dissemination
(Eddy, 1991), and implementation of the guidelines (Eddy, 1990).
Clinical Practice Guidelines (CPGs) is a project initiated by the
Centre Le ￿on Be ￿rard, a comprehensive cancer centre in Lyon
(France), as part of the institution’s quality management
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www.bjcancer.comprogramme. The development, implementation and evaluation of
the impact of the CPGs on medical practice in one comprehensive
cancer centre have already been reported (Ray-Coquard et al,
1997). An increased number of medical decisions compliant with
the CPGs were reported in this study (Ray-Coquard et al, 1997).
At the same time as this previous study, the cancer centre provided
leadership in the Rho ˆne-Alpes region for cancer treatment and
developed a managed care network model similar to those
previously described (Siren and Laffel, 1996). This approach was
initiated in 1995, when hospitals located in the Rho ˆne-Alpes region
in France were invited to participate in the elaboration of a regio-
nal cancer network: ONCORA (ONCOlogy Rho ˆne-Alpes). The
aims of this regional project, which was organized on the basis
of voluntary participation, were: (1) to assist hospital-based oncol-
ogists in their decision-making (Fink et al, 1984); (2) to minimize
inappropriate variation in practice (Farrow et al, 1992); (3) to opti-
mize health beneﬁt; and (4) to rationalize prescriptions of
chemotherapy. The cancer network development plan involved
the implementation of the CPGs elaborated in the cancer centre.
We conducted a controlled ‘before-after’ study to evaluate the
impact of the CPGs and the implementation strategy in the cancer
network. An external medical record audit process was set up in
the two regions to assess the impact of CPGs on the diagnostic
and treatment practice and for breast and colon cancer: Rho ˆne-
Alpes, with its regional cancer network organization, was the
experimental group, and an anonymous matched control region
which does not have either a regional cancer network, a process
of guidelines implementation, or structures for co-ordinating clin-
ical practice at the time of the data collection, was the control
group.
METHODS
Objectives
We assessed the impact of the introduction of the CPGs in the
regional cancer network on the management of breast and colon
cancer by comparing the compliance of medical practice with the
CPGs between the two matched groups of hospitals. When medical
decisions were judged to be non-compliant, we veriﬁed if they were
based on scientiﬁc evidence in a published article.
Criteria for hospitals, region and tumours selection
Regions The experimental region is Rhone-Alpes (France), where
the CPG programme was implemented, which belongs to Frances’s
regional cancer network: ONCORA. The control region was one
that did not participate in the CPG program, or in the ONCORA
regional cancer network organization. The control region was
selected to be similar to the experimental region with respect to
the presence of medical school training and teaching hospitals
(although teaching hospitals were excluded), a mix of private
and public institutions, and more than 5000 newly diagnosed
cancers reported annually.
Institutions Each group had to include institutions that were
from both private and public sectors. To be eligible, each hospital
had to be able to produce at least 50 new patient records treated
for breast or colon cancer for each time period, and participation
was voluntary. To qualify for the experimental group, a hospital in
the Rhone-Alpes region had to be participating in regional cancer
network activities since 1995.
Tumors Localized breast cancer and colon cancers (of any stage)
were selected because of the adapted representation of these two
tumours for the medical practice in oncology and in the network
(frequency, numerous sources of evidence for breast cancer, few
for colon cancer).
Setting
Experimental group ONCORA is a cancer network located in
the Rho ˆne-Alpes region (France). This region (with an area of
43500 km
2 and 5.5 million inhabitants) has about 100 public
hospitals (with four teaching hospitals) and 87 private hospitals,
providing a total of about 26000 beds). The ONCORA network
covers 11 private and 15 public hospitals within this region with
a total of about 5500 beds. Approximately 17000 new malignant
tumours are treated annually in the Rho ˆne-Alpes area and 40%
are treated within the organized cancer network. Because of the
participating date of 1995, and the number of required records
for breast and colon cancer, only four hospitals satisfy the selection
criteria (three public and private structures) and all of them
accepted to participate in the evaluation of the impact of the CPGs.
These four structures were ﬁnancially organization, and geographi-
cally typical of ONCORA as a whole.
Control group The control region (with an area of 27000 km
2
and 2.3 million inhabitants) has about 40 public hospitals (with
three teaching hospitals) and 80 private hospitals, providing a total
of about 11000 beds). Approximately 9000 new malignant tumours
are treated annually in this region. Three of the four hospitals with
an activity sufﬁcient to satisfy the selection criteria, agreed to parti-
cipate (two public and one private structures).
Intervention: cancer network development and
implementation strategy of the CPGs
Physicians and administrative staff from 26 public or private
general hospitals of the 40 hospitals with a sufﬁcient level of
oncology activity located in the experimental region, agreed to
participate in the network and accepted the principles of the
implementation of CPGs and evaluation by an external audit
procedure. The implementation of the CPGs involved monthly
meetings in 1995. Each meeting concentrated on a speciﬁc cancer
site. Local opinion leaders (from the cancer centre), who were
both knowledgeable and credible for the speciﬁc cancer site,
presented the relevant sections of the CPGs. The information
was then discussed, modiﬁed and/or validated by all the partici-
pating physicians from the 26 hospitals to obtain a regional
consensus. Two weeks after the meeting, the validated CPGs were
sent to all the participating physicians who were expected to use
them in their practice. However, no speciﬁc penalty or reward
system was included in this implementation strategy. At the end
of 1995, all the participating physicians agreed to publish the
CPGs as a booklet and a computer programme, which can be
integrated in hospital information systems (Centre Le ￿on Be ￿rard
Re ￿seau ONCORA, 1997).
Study design
This controlled ‘before-after’ study, using institutional records of
breast and colon cancer patients was conducted in 1994 (the
period ‘before’ implementation of the CPGs in ONCORA), and
in 1996 (the period ‘after’ when the CPGs had been fully imple-
mented for 1 year). These 2 years were selected because the
‘state-of-the-art’ treatment had not been dramatically modiﬁed
over this period. This stability is witnessed by the lack of publi-
cations of substantial results of studies concerning the
management of localized breast cancer over this period.
However, for colon cancer, the results of a highly positive rando-
mized controlled trial in metastatic disease were presented in
1995 (de Gramont et al, 1995) and published in 1997 (de
Gramont et al, 1997), and this may have resulted in a modiﬁca-
tion of medical practice. The analyses for colon cancer were,
therefore, stratiﬁed according to a modiﬁed Duke’s classiﬁcation
to control for this potential bias.
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The data were collected (by one of the authors (I Ray-Coquard,
medical oncologist and a technician) and analyzed by one of the
authors (I Ray-Coquard) working independently of the practi-
tioners caring for patients in the different hospitals. It was
impossible to do this analysis blinded to the year of treatment since
the data were obtained directly from the patients’ records. To
control the extracted data, a random 10% sample was rechecked
by the same ratter, blinded to the previous decision. The physician
agreement rate with the original decision was 95% (kappa
test=0.89). In addition, the experts from the Centre Le ￿on Be ￿rard
conﬁrmed the decisions for this sample.
Selection of patients’ records
For this kind of study, at least 50 patient’s records were necessary
to detect a statistically signiﬁcant increase in the compliance rate.
Because of the recruitment of the institutions, all the records of
localized breast cancer were selected in ﬁve of the hospitals, but
in two (one in the control group, one in the experimental group),
due to their high recruitment, a computerized procedure (random
numbers) was used to select 100 from about 300 women with loca-
lized breast cancer for both years. Randomly selected patients who
were not eligible were excluded and other patients were randomly
selected to replace them. The eligibility criteria for breast cancer
selected only records for women with newly referred localized
breast cancer (in situ and invasive breast carcinoma) in 1994 and
1996. A record was considered to be assessable if surgical biopsy
for breast cancer had been reported. We selected all the records
for new colon cancer patients in 1994 and in 1996, but one centre
in the intervention group did not have any patients with colon
cancer, thus only six hospitals were analyzed for colon cancer. Elig-
ibility criteria for colon cancer included newly referred women or
men in 1994 and 1996, with any stage of cancer.
Measurements
The main outcome was the number of overall treatment sequences
judged to conform with the CPGs. The overall treatment sequence
included the decisions for each type of procedure individually
(surgery, radiotherapy, chemotherapy, hormonal therapy, initial
examination, follow-up). Each of those procedures were assessed
for conformity with the recommendations in the CPGs. Finally,
the overall treatment sequence was judged to conform if all the
assessable component procedures were followed. Only medical
decisions covered by the CPGs were taken into consideration in
the assessment of compliance. We decided to use the overall treat-
ment sequences (i.e. a sequence of decisions along a management
pathway) because it is possible that medical decisions by type of
procedures were not independent of each other. For example,
surgeons could present only patients records with localized breast
cancer and node involvement to the medical oncologist for
chemotherapy indication. However, results for each type of proce-
dure individually were presented to understand why guidelines
had not been followed. Figure 1 shows an example of these trans-
lated decisional algorithms of adjuvant chemotherapy indication
for breast cancer patients with node involvement. Only the initial
overall treatment sequence including surgery, radiotherapy,
chemotherapy and hormonal therapy with initial examination
and follow-up (when these were performed in the participating
hospital) were taken into account. Hence, only one overall treat-
ment sequence could be assessed for each patient. For colon
cancer, data for both initial treatment and relapses were considered
C
l
i
n
i
c
a
l
Localized breast cancer N+
³8 N+ ?
No Yes
Menopausal status
No menopausal woman Menopausal woman
ONCORA recommendations:
- 4 courses AC protocol
  if anthracyclines contraindicated:
6 courses of CMF
- or Phase III study PEGASE 01
No menopausal woman Menopausal woman
Hormonal
receptors ONCORA recommendation:
hormonal therapy by
Tamoxifen 20 mg (5 years)
ER and/or PR + ER and PR -
No hormonal therapy ONCORA recommendation:
hormonal therapy by
Tamoxifen 20 mg (5 years)
without ovarian castration
ONCORA recommendations:
- 4 courses of AC protocol or
  if anthracyclines contraindicated:
  6 courses of CMF regimen
-- if ER+/PR+     hormonal therapy by
  tamixofen (5 years) without castration
- if ER-/PR-     no hormonal therapy
ONCORA recommendations:
- ≤ 70 years : 4 courses of AC protocol
  if anthracyclines contraindicated :
  6 courses of CMF regimen
- > 70 years old tamoxifen 5 years and
  chemotherapy adjuvant indication
- or phase III study GFEA 08
ER- PR: oestrogene or progesterone receptors
N+: positive node involvements
Adjuvant chemotherapy
Figure 1 Example of decisional algorithms.
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ment, hence, several overall treatment sequences could be
assessed for colon cancer patients.
The second level of conformity was the number of medical deci-
sions judged to be based on either the CPGs or published
randomized trials i.e. ‘evidence-based’ by performing a systematic
literature search using a documented strategy as developed by
Sackett (1989). On the basis of the evidence unearthed in this
way all types of procedure were individually classiﬁed by the
blinded experts of the comprehensive cancer centre (one professor,
six senior house ofﬁcers, four residents and three students) as being
‘evidence-based’ if they complied with the CPGs’ recommendations
or were judged to be based on scientiﬁc evidence (scientiﬁc-level
graded from I to II (Sackett, 1989)), or if they had been established
in one or more RCTs or overviews of RCTs. When no published
randomized trials were identiﬁed for at least one individual medi-
cal decision, the overall treatment sequences was classiﬁed as
having ‘no convincing supporting scientiﬁc evidence’.
Statistical analysis
Compliance was scored as 1 if the recommendations was followed
and as 0 if not. Categorical data were analyzed using the Pearson w
2
or Fisher exacts test, as appropriate. Continuous data were
analyzed with Student’s t-test. The statistical signiﬁcance level
was set at P=0.05 in a two-sided test. Univariate analyzes were
performed to assess if the patients’ characteristics were correlated
with compliance or non-compliance with the CPGs. A Mantel–
Haenszel w
2 test (Mantel, 1963) stratiﬁed on centre was performed
to assess concordance between the overall results and the individual
hospital results. A Mantel–Haenszel w
2 test, stratiﬁed on the stage
of the colon cancer was performed to evaluate the impact of the
publication of the results for new chemotherapy regimens for the
treatment of metastatic colon cancer (de Gramont et al, 1995,
1997) on medical practice.
RESULTS (BREAST CANCER)
Patients’ characteristics
In the experimental group, 37 (10%) and 21 (6%) of the 319 and
367 records selected in 1994 and 1996, respectively, did not satisfy
the selection criteria. In the control group 18 (8%) and 40 (19%)
of the 212 and 210 records selected in 1994 and 1996, respectively,
were not assessable for overall treatment sequence (Table 1).
For both groups of patients, some records were not assessable
for certain type of procedures individually. Table 1 summarizes
the reasons for non-evaluation of these procedures. For both
groups of hospitals, the characteristics of the patients were similar
for the 2 years (Table 2).
Compliance rate with CPGs
Experimental group The observed compliance rate with CPGs
for the 628 assessable overall treatment sequences was signiﬁcantly
higher in 1996 (36%; 125 out of 346) than that in 1994 (12%; 34
out of 282). In addition the number of individual medical deci-
sions complying with the CPGs was also signiﬁcantly higher in
1996 than in 1994 (Table 3).
Control group We detected no difference in the observed compli-
ance rate with CPGs for the 366 assessable overall treatment
sequences in 1996 (7%; 12 out of 172) and in 1994 (6%; 12 out
of 194). The number of individual medical decisions complying
with the CPGs was also similar for the 2 years (Table 3).
The compliance rate for surgery for patients aged 75 or over (79
out of 92 and 25 out of 46, in the experimental and control groups,
respectively) was signiﬁcantly lower than that for patients under 75
years of age (498 out of 536 and 269 out of 320, in the experimen-
tal and control groups, respectively) P50.01).
The number of overall treatment sequences complying with the
CPGs in each hospital in the experimental group was signiﬁcantly
higher in 1996 than in 1994 (results not shown). No change was
noted for the hospitals in the control group (results not shown).
The initial compliance rate with the CPGs i.e. in 1994, was signiﬁ-
cantly different between the control and the experimental groups of
patients (6% vs 12%, P=0.03).
‘Evidence-based’ decisions and ‘no convincing scientiﬁc
evidence’ decisions
For the experimental group, in 1994, 47% (95% CI, 41–53) (132
out of 282) and in 1996, 62% (95% CI, 54–64) (214 out of 346)
(P50.001) of initial treatments were conform with the CPGs or
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Table 1 Characteristics of non-assessable breast cancer patients
Non assessable records or procedures 1994 1996 Reasons for non-assessment
Patient records Metastatic disease
In experimental group 37 21 Non ductal carcinoma
In control group 18 40 Patients refused surgery
Type of procedure
1 Initial examination
In experimental group 34 21 Diagnosis and staging occurred elsewhere,
In control group 2 0 outside the participating institutions
2 Follow-up Follow-up occurred elsewhere
In experimental group 29 35 Early relapse
In control group 21 28 Follow-up is on-going
3 Chemotherapy
In experimental group 3 2 No axillary dissection
In control group 4 4 Chemotherapy contraindicated
4 Radiation therapy
In experimental group 3 7 Radiotherapy occurred elsewhere
In control group 2 5
5 Hormonal therapy Hormonal therapy occurred elsewhere
In experimental group 1 4 Missing data
In control group 2 2 Treatment contraindicated
Prior therapy by tamoxifen
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group these results were 90 out of 194 in 1994 (46%; 95% CI,
39–53) and 80 out of 172 in 1996 (47%; 95% CI, 39–54),
P=0.98. The medical decisions for 1994 and 1996, not covered
by the CPGs but based on scientiﬁc evidence are summarized in
Table 4.
In 1994, 101 of the 282 medical decisions in the experimental
group (36%; 95% CI, 30–42) were classiﬁed as having ‘no convin-
cing scientiﬁc evidence’ compare with 72 out of 346 in 1996 (21%;
95% CI, 17–25), P50.001. In the control group these results were
96 out of 194 in 1994 (49%; 95% CI, 42–56) and 87 out of 172 in
1996 (51%; 95% CI, 44–58), P=0.91.
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Table 2 Characteristics of breast cancer patients with assessable records
Experimental group Control group
1994 1996 P 1994 1996 P
Patients number (%) 282 (100) 346 (100) 194 (100) 172 (100)
Age (years) 0.49 0.12
Median 60 60 59 57
Range 26–98 30–91 24–94 24–92
Stage (UICC)
a number (%) 0.37 0.72
In-situ carcinoma 25 (9) 22 (6) 6 (3) 6 (4)
T1 1128 (45) 164 (47) 79 (41) 82 (47)
T2 105 (37) 141 (41) 95 (49) 72 (42)
T3 16 (6) 14 (4) 13 (7) 12 (7)
T4 (inﬂammatory) 8 (3) 5 (2) 1 (1) 1 (1)
Tumour size (mm) 0.30 0.97
Median 18 17 19 16
Range 0–200 0–160 0–170 2–110
Involved nodes number (%) 0.33 0.58
Yes 112 (40) 129 (37) 63 (33) 53 (31)
No 163 (56) 211 (61) 130 (67) 120 (69)
Unknown 7 (2) 6 (2) 1 (1) 0 (0)
Nodes examined number (%) 0.13 0.16
Median 12 11 12 12
Range 0–30 0–29 0–24 0–25
Hormone receptors number (%) 0.15 0.31
Positive 164 (58) 211 (61) 127 (66) 112 (65)
Negative 56 (20) 90 (26) 45 (23) 33 (19)
Unknown 62 (22) 45 (13) 22 (11) 28 (16)
Scarf Bloom Richardson score number (%) 0.70 0.09
Grade I 53 (19) 80 (23) 22 (13) 32 (20)
Grade II 103 (36) 137 (40) 84 (49) 76 (48)
Grade III 57 (20) 66 (19) 50 (29) 30 (19)
Not tested
b 33 (12) 38 (11) 16 (9) 20 (13)
Missing data 36 (13) 25 (7) 22 (11) 15 (9)
aUICC: Union Internationale Contre Le Cancer (1988).
bLobular carcinoma.
Table 3 Compliance rates for medical decision by type of procedure
Experimental group Control group
No. decisions
assessed % compliant with CPGs (95% CI)
No. decisions
assessed % compliant with CPGs (95% CI)
Type of procedure 1994 1996 1994 1996 P 1994 1996 1994 1996 P
Breast cancer
Initial examination 252 328 73 (68–78) 86 (82–90) 50.001 192 172 64 (57–70) 58 (50–65) 0.17
Surgery 282 346 89 (85–93) 94 (91–97) 0.02 194 172 77 (71–83) 84 (79–89) 0.11
Chemotherapy 279 344 66 (60–72) 78 (74–82) 50.001 190 168 66 (59–72) 676 (60–74) 0.37
Radiotherapy 279 344 71 (66–76) 77 (73–81) 0.04 187 167 49 (42–56) 50 (42–57) 0.42
Hormonal therapy 281 342 73 (68–78) 79 (75–83 0.03 192 172 77 (71–82) 74 (67–80) 0.46
Follow-up 253 291 41 (35–47) 81 (76–86) 50.001 173 144 8 (4–12) 12 (7–17) 0.13
Overall treatment sequence 282 346 12 (8–16) 36 (30–42) 50.001 194 172 6 (3–9) 7 (3–11) 0.46
Colon cancer
Initial examination 47 60 92 (82–98) 100 0.03 67 94 68 (57–79) 70 (61–79) 0.48
Surgery 103 123 100 100 88 122 97 (93–100) 98 (95–100) 0.35
Chemotherapy 102 123 16 (9–23) 47 (38–56) 50.001 93 121 44 (34–54) 57 (48–66) 0.09
Follow-up 47 33 74 (63–87) 97 (91–100) 0.005 48 62 67 (54–80) 57 (45–69) 0.18
Overall treatment sequence 103 123 14 (7–21) 46 (30–54) 50.001 96 126 32 (23–41) 39 (40–57) 0.19
aOverall treatment sequence: surgery, radiotherapy, chemotherapy and hormonal therapy with initial examination and follow-up if they were performed in the participating
hospitals.
bOverall treatment sequence: surgery and chemotherapy with initial examination and follow-up, if they were applicable and performed in the participating hospitals.
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sive (132 patients in the experimental and 237 patients in the control
group), or over-frequent measurement of tumour markers during
follow-up. For chemotherapy, this was due to the prescription of
regimens that were not validated in the adjuvant phase. For radio-
therapy, this was due to the absence of adjuvant irradiation after
conservative surgery for elderly patients, absence of sub-clavicular
irradiation for an internal tumour site with nodal involvement, adju-
vant irradiation of regional lymph nodes for an external small node
negative tumour, and radiation therapy after axillary dissection. For
hormonal therapy, this was due to absence of adjuvant treatment for
menopausal patients with positive hormone receptors or adjuvant
hormonal therapy for carcinoma in situ. For surgery, the reasons
were no axillary dissection for elderly patients, or radical mastectomy
for patients with a tumour smaller than 3 cm instead of conservative
surgery and adjuvant irradiation; conservative surgery and adjuvant
irradiation for patients with a tumour larger than 4 cm rather than
radical mastectomy; no axillary dissection for management of plur-
ifocal carcinoma in situ and conservative surgical treatment of retro-
areolar breast tumours in the experimental group.
RESULTS (COLON CANCER)
Patients’ characteristics
In the experimental group, 95 and 94 records for newly referred
patients with colon cancer were eligible for inclusion in 1994 and
1996, respectively, corresponding to 103 and 96 overall treatment
sequences. In the control group, 89 and 118 records for newly
referred patients with colon cancer were eligible for inclusion in
1994 and 1996 respectively, corresponding to 96 and 126 overall
treatment sequences. The CPGs contained no guidelines concerning
initial examination and follow-up for metastatic disease, and, thus,
only a few medical decisions were assessable for these aspects of
practice. For the two groups (experimental and control) only 80
and 110 records, respectively, were assessable for follow-up, either
because this occurred elsewhere, the patient had died, or early
relapse at the time of the analysis. The patients from the hospitals
in the experimental group treated in 1996 were signiﬁcantly older
than those seen in 1994 and more patients had more than one
therapeutic sequence in 1996 than in 1994 (Table 5). There were
no differences in the patients from the control group hospitals.
Compliance rate with CPGs
Experimental group The observed compliance rate with CPGs for
the assessable overall treatment sequences was signiﬁcantly higher in
1996 (46%; 57 out of 123) than in 1994 (14%; 14 out of 103). In addi-
tion the number of individual medical decisions complying with the
CPGs was also signiﬁcantly higher in 1996 than that in 1994 except
for surgical procedures (Table 3). The Mantel–Haenszel w
2 test stra-
tiﬁed on stage (local vs metastatic) showed that the compliance rate
for the overall treatment sequence was higher in 1996 than in 1994
for any stage of the disease (P50.001) in this group.
Control group We detected no difference in the observed
compliance rate with CPGs for the assessable overall treatment
sequences in 1996 (32%; 31 out of 96) and in 1994 (39%; 49
out of 126) P=0.19. The number of individual medical decisions
complying with the CPGs was also similar for the 2 years (Table 3).
For both groups of patients in 1994 and in 1996, the results
from univariate analyzes showed no statistically signiﬁcant correla-
tion between patients’ characteristics (tumour markers,
performance status, tumour stage, age, number of therapeutic lines
per patients) and medical decisions.
The number of overall treatment sequences complying with the
CPGs in each hospital in the experimental group was signiﬁcantly
higher in 1996 than in 1994 (results not shown). No change was
noted for the hospitals in the control group (results not shown).
The initial compliance rate with the CPGs i.e. in 1994, was signiﬁ-
cantly different between the control and the experimental groups of
patients (14% vs 32%, P=0.01).
‘Evidence-based’ decisions and ‘no convincing scientiﬁc
evidence’ decisions
For the experimental group, in 1994, 74% (95% CI, 65–82) (76
out of 103) and in 1996, 86% (95% CI, 80–92) (106 out of
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Table 4 Medical decisions compliant with CPGs but based on ‘scientiﬁc evidence’ with the level of evidence graded I to II (de Gramont et al, 1997)
Scientiﬁc Experimental Control
Source (year) Indications Management observed level group (n=204) group (n=170)
Breast cancer n (%) n (%)
Coombes et al, 1996 Adjuvant chemotherapy Anthracyclin chemotherapy regimen II (1) 93 (46) 37 (22)
EBCTCG
a, 1992 Menopausal patients, ER+ and No chemotherapy I (3) 16 (8) 16 (9)
hormonal therapy
EBCTCG
a, 1996 Pre menopausal patient Ovarian ablation I (2) 34 (17) 26 (15)
EBCTCG
a, 1992 Hormonal receptor negative No hormonal therapy I (3) 33 (16) 32 (19)
EBCTCG
a, 1992 Pre menopausal patient, N7, ER+ Hormonal therapy I (3) 4 (2) 7 (4)
Federation Nationale des Centres Tumour size 530 mm and mastectomy No adjuvant chest wall radiation II (3) 8 (4) 20 (12)
de Lutte Contre le Cancer, 1996
Fisher et al, 1995a Carcinoma in situ Adjuvant radiation therapy II (2) 4 (4) 5 (3)
Ruqvist et al, 1990 Tumour size 430 mm Lymph nodes radiation II (3) 6 (3) 24 (14)
Fisher et al, 1995b Tumour size 440 mm Conservative surgery II (2) 6 (3) 3 (2)
Colon cancer (n=112) (n=55)
Moertel et al, 1990 Chemotherapy in adjuvant phase Fluorouracil and levamisole II (1) 11 (10) 1 (2)
Petrelli et al, 1987 Chemotherapy in metastatic phase Fluorouracil and high dose lecovorin II (2) 19 (17) 1 (2)
Buroker et al, 1994 Chemotherapy in metastatic phase Fluorouracil and low dose lecovorin II (2) 18 (16) 20 (36)
Scheithauer et al, 1993 Chemotherapy in adjuvant phase Fluorouracil and lecovorin with cisplatin II (3) 2 (2) 0 (0)
Wolmark et al, 1993 Chemotherapy in adjuvant phase Fluorouracil and high dose lecovorin II (3) 56 (5) 0 (0)
IMPACT investigators, 1995 Stage B2 (Asler and Coller, 1954) No adjuvant chemotherapy I (2) 5 (4) 18 (33)
Federation Nationale des Centres Follow-up for stage A and B1 Only colonoscopic follow-up II (3) 0 (0) 12 (22)
de Lutte Contre le Cancer, 1995
Rougier et al, 1992 Chemotherapy in adj. phase Hepatic arterial infusion II (2) 1 (1) 5 (9)
aEBCTCG=Early Breast Cancer Trialists’ Collaborative Group; In adj. phase=in adjuvant phase; In met. phase=in metastatic phase.
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judged to be based on scientiﬁc evidence, P50.001. In the control
group these results were 61 out of 96 in 1994 (64%; 95% CI, 54–
74) and 75 out of 123 in 1996 (61%; 95% CI, 52–70), P=0.69. The
medical decisions for 1994 and 1996, not covered by the CPGs but
based on scientiﬁc evidence are summarized in Table 4.
In the experimental group, 26% (27 out of 103; 95% CI 17–34),
and 17% (21 out of 123; 95% CI 10–23) (P=0.09) of the medical
decisions in 1994 and 1996, respectively, were classiﬁed as ‘having
no convincing scientiﬁc evidence’. In the control group 29% of the
medical decisions (28 out of 96; 95% CI, 20–38) in 1994 and
24% (30 out of 126; 95% CI, 17–31) (P=0.40) in 1996 were
judged as ‘having no convincing scientiﬁc evidence’. These deci-
sions concerned adjuvant radiation therapy, and radiation
therapy for liver metastases. The non-compliant medical
decisions concerning chemotherapy procedures, were no
adjuvant or palliative chemotherapy for elderly patients,
prescription of adjuvant chemotherapy regimen for stage B1,
absence of adjuvant chemotherapy for stage C and prescription
of non-validated chemotherapy regimens instead of campthotecin.
DISCUSSION AND CONCLUSIONS
In this controlled ‘before-after’ study of medical decisions we
report an increase in the number of medical decisions compliant
with CPGs in the experimental group compared with that in the
matched control group. The baseline rates appeared to be very
different, indicating that hospitals did not have the same baseline
of conformed medical decisions for cancer management. However,
it is the difference between the time periods for the two groups,
which is important for the comparison rather than the comparison
between the two groups. In the experimental group, for breast
cancer the most frequent modiﬁcation of practice concerned less
extensive follow-up after treatment. More importantly, mastectomy
rate for tumours smaller than 30 mm was zero. This approach of
local management for early breast cancer had been shown to be
efﬁcient in randomized controlled trials since 1989 (Sarrazin et
al, 1989). In 1994, 17% (9 out of 52) mastectomy were performed
rather than conservative treatment in the experimental group vs
35% (24 out of 69) in the control group! Although there was a
higher percentage increase of compliance with CPGs from 1994
to 1996 in the control hospitals than in the experimental hospitals
for surgery (7% vs 5%), this was not statistically signiﬁcant. The
explanation is partly due to the rate of mastectomy for small
tumours which decreased in the control group between 1994 and
1996 (24 out of 69, 35% vs 13 out of 49, 26%, respectively). For
colon cancer, we observed a higher conformity with the CPGs in
1996 than in 1994 for all procedures except surgery. The most
frequent modiﬁcation was the choice of chemotherapy regimen
and the less frequent modiﬁcation was the use of chemotherapy.
The median increase in compliance in the experimental group
was 10% by type of procedures, which, although signiﬁcant,
remained modest, but the baseline compliance was superior to
70%. However, a conformity rate of 100% is probably impossible
to obtain irrespective of the guidelines evaluated, essentially
because of the patients’ characteristics and preferences! For the
overall treatment sequence, the baseline rate and the percentage
in 1996 were less than 50% mainly because only one deviation
in the procedure modify the compliance rate. This could be
explained by the fact that follow-up care rarely deviates from
conformity and that there were no major deviations for some
patients and only minor deviations for many patients.
The results from this study suggest that the implementation of
the CPGs in the network was effective, since modiﬁcations were
observed compared with the practice in the control group. Inter-
ventions based on group dynamics and sensitive to the local
practice context have been shown to be useful in facilitating the
adoption of guidelines by physicians. Other methods, for example,
consensus conferences, have been reported to have little or no
effect on physicians in hospital practice (Kosecoff et al, 1987).
The results observed in the network hospitals were similar to those
previously reported for one comprehensive cancer centre (Ray-
Coquard et al, 1997).
Although the conformity rates in 1994 in this multicentric study
were lower than those reported for the single hospital, the rate
increase was of a similar size. Moreover, this result was observed,
despite the fact that the physicians in the other network hospitals
did not elaborate the CPGs, although they had validated them.
As in the previous study (Ray-Coquard et al, 1997), it is very
encouraging to note for the experimental group that 62% of the
medical decisions were evidence-based as deﬁned by Ellis (Grim-
shaw and Russell, 1993) in 1996 which compares favourably with
the 47% observed in 1994, although there was no modiﬁcation
in the control group (46% vs 47%). Although the practitioners
in the network did not established that their decisions could be
supported by evidence (this was retrospectively realized by the
authors), the results of the study would suggest that introducing
guidelines modiﬁes medical practice, making it more conformed
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Table 5 Characteristics of colon cancer patients with assessable records
Experimental group Control group
1994 1996 P 1994 1996 P
Patients number (%) 95 (100) 94 (100) 89 (100) 118 (100)
Age (years) 0.01 0.83
Median 66 69 68 68
Range 16–91 43–92 32–96 36–94
Stage (Asler and Coller, 1954) number (%) 0.75 0.36
A 2 (2) 1 (1) 6 (7) 5 (4)
B1 5 (5) 3 (3) 7 (8) 4 (3)
B2 24 (25) 19 (20) 21 (22) 32 (27)
C 35 (37) 41 (43) 25 (28) 37 (31)
D 29 (31) 30 (29) 30 (34) 40 (34)
Performance status (Karnofsky scale) number (%) 0.25 0.35
80–100 72 (84) 76 (88) 75 (87) 104 (90)
580 14 (16) 10 (12) 12 (13) 13 (10)
Therapeutic lines/patient number (%) 0.006 0.35
1 89 (94) 71 (76) 82 (93) 103 (87)
2 4 (4) 17 (18) 7 (7) 14 (12)
3 2 (2) 6 (6) 0 (0) 1 (1)
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based medicine. Establishing the infrastructure for practicing
evidence-based medicine cost money (one million dollars each year
for the organization of the ONCORA network) but practice guide-
lines and practicing medicine seems to be compatible.
It is most difﬁcult to understand why practitioners in the
network made evidence-based practice decisions that were not in
accordance with the CPGs. For example, four cycles of AC (adria-
mycine plus cyclophosphamide) is the chemotherapy regimen
recommended in adjuvant phase in the CPGs (Figure 1) but six
cycles of FEC 100 (ﬁve Fluorouracile, epirubicin plus cyclopho-
sphamide) (Coombes et al, 1996) was an ‘evidence-based
chemotherapy regimen’ and for some young patients with very
poor prognosis this attitude seems adapted without questioning
the validity of the guidelines project. This kind of decision has
always been very difﬁcult to analyze retrospectively and interpreta-
tion leads to only hypotheses and not evidence.
In our study, the retrospective data collection may have offered
some advantages over a prospective randomized study since, with a
prospective data collection, there could have been ‘contamination’
in the control group, if the physicians had been aware of the study
(Russell and Grimshaw, 1992; Ellis et al, 1995). In addition, the
hospitals had volunteered and it would have been unrealistic to
randomize the institutions and, then ask them to participate in
the evaluation. Hence, we decided that a stratiﬁed analysis was
necessary as seven centres were assessed. One limitation of this
study would be a lack of comparability between the two regions.
The control setting is about half the size of the experimental setting
for most variables measured, although the number of new cancer
patients managed every year was similar in each group and the
population size was the most important predictor of decision qual-
ity and reproducibility (Glasgow et al, 1999).
We plan to assess if the diffusion of the results (feedback)
presented here, will modify the medical practice of the physicians,
since this has not always been reported to be effective (Lomas et al,
1991) and we also plan to assess the stability of this level of
compliance over time, after the intensive implementation strategy
has discontinued (Tierney et al, 1990). Future research should
explore questions such as: what does making medical decisions
more compliant with the CPGs mean? And how does this modify
practice? For example, would changing the payment system modify
prescription behavior (Rice, 1983)? A further problem is that there
is no clear threshold of ‘acceptable’ compliance above which we
could consider that the CPGs have been implemented well. It
would be completely unrealistic to set this threshold at 100%,
but we need to deﬁne a meaningful limit. These questions must
be answered so that we can create more effective methods for
involving physicians in quality assurance programmes.
The results in this study show that by adapting the external
dissemination process, it is possible to reach a consensus for the
CPGs in a target audience, and thus bring about a behaviour
change (Delamothe, 1993). When applied to physicians in commu-
nity hospitals, our educational strategy of opinion leaders
performing ‘detailing based on the CPGs’ produced a signiﬁcant
change in the behaviour.
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